VIDEO: Expert discusses approvals for multiple myeloma, upcoming clinical trial data
Click Here to Manage Email Alerts
The last year has seen important FDA approvals for the treatment of multiple myeloma and the upcoming year promises updates from ongoing clinical trials.
“We’re really excited about 2023 in myeloma because we got two new products approved by the FDA last year and that includes two bispecific antibodies,” said Samer Al Hadidi, MD, MS (CRDSA), FACP, an assistant professor at Winthrop P. Rockefeller Cancer Institute at University of Arkansas for Medical Sciences. “One is called elranatamab [Elrexfio, Pfizer] and the second one is called teclistamab [Tecvayli, Janssen].”
Looking to the coming year, Al Hadidi also discussed trial data he will be keeping his eye on.
“There will always be clinical trials that we are waiting for it to be read in the coming year — or years, to be honest with you — and some of those include different clinical questions that we ask in the clinic,” Al Hadidi said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts